Daniel G Haller

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Safety of oxaliplatin in the treatment of colorectal cancer
    D G Haller
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 14:15-20. 2000
  2. ncbi request reprint Update on chemotherapy for advanced colorectal cancer
    D G Haller
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:11-5. 2001
  3. ncbi request reprint Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes
    Adam C Berger
    Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 23:8706-12. 2005
  4. doi request reprint Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
    Weijing Sun
    Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, 19104 4283, USA
    Cancer Chemother Pharmacol 67:621-7. 2011
  5. doi request reprint Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
    Weijing Sun
    Abramson Cancer Center, Department of Medicine, Hematology Oncology Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer 117:3187-92. 2011
  6. doi request reprint Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19014 4283, USA
    J Clin Oncol 26:4544-50. 2008
  7. doi request reprint Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Ursina R Teitelbaum
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Nat Rev Clin Oncol 6:250-1. 2009
  8. ncbi request reprint Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
    Daniel G Haller
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 23:8671-8. 2005
  9. ncbi request reprint Adjuvant therapy of colon cancer
    Weijing Sun
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Semin Oncol 32:95-102. 2005
  10. doi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008

Detail Information

Publications77

  1. ncbi request reprint Safety of oxaliplatin in the treatment of colorectal cancer
    D G Haller
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 14:15-20. 2000
    ..Cumulative neurotoxicity is the dose-limiting toxicity associated with oxaliplatin treatment. This toxicity appears reversible with discontinuation of the drug and typically occurs well after the onset of tumor response...
  2. ncbi request reprint Update on chemotherapy for advanced colorectal cancer
    D G Haller
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:11-5. 2001
    ....
  3. ncbi request reprint Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes
    Adam C Berger
    Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 23:8706-12. 2005
    ..Colorectal cancer is the second leading cause of cancer deaths in the United States, with poor survival predicted by regional lymph node (LN) metastasis. The impact of LN ratio (LNR) on survival is unknown in this disease...
  4. doi request reprint Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
    Weijing Sun
    Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, 19104 4283, USA
    Cancer Chemother Pharmacol 67:621-7. 2011
    ..Epirubicin, cisplatin, and irinotecan are active cytotoxic chemotherapy agents in UGI cancers...
  5. doi request reprint Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
    Weijing Sun
    Abramson Cancer Center, Department of Medicine, Hematology Oncology Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer 117:3187-92. 2011
    ..This phase 2 study was designed to determine the efficacy and toxicity of the combination of bevacizumab, capecitabine, and oxaliplatin in patients with advanced unresectable and untransplantable HCC...
  6. doi request reprint Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19014 4283, USA
    J Clin Oncol 26:4544-50. 2008
    ..Patients received IROX (irinotecan 200 mg/m(2) plus oxaliplatin 85 mg/m(2)) or irinotecan alone (350 mg/m(2)) every 3 weeks...
  7. doi request reprint Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Ursina R Teitelbaum
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Nat Rev Clin Oncol 6:250-1. 2009
    ..This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens...
  8. ncbi request reprint Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089
    Daniel G Haller
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 23:8671-8. 2005
    ..Intergroup (INT) 0089 assessed the relative contributions of leucovorin and levamisole in such patients...
  9. ncbi request reprint Adjuvant therapy of colon cancer
    Weijing Sun
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Semin Oncol 32:95-102. 2005
    ..Novel molecular and biologic-oriented agents are being studied. Further analysis and definition of prognostic and predictive markers may allow future adjuvant therapy to be individualized...
  10. doi request reprint Potential regional differences for the tolerability profiles of fluoropyrimidines
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:2118-23. 2008
    ....
  11. doi request reprint Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer
    Daniel G Haller
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Clin Oncol 29:1465-71. 2011
    ..This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cancer...
  12. ncbi request reprint Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow
    James P Stevenson
    University of Pennsylvania, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    J Clin Oncol 21:4428-38. 2003
    ..The present study investigated escalating doses of CA4P administered intravenously to patients with advanced cancer...
  13. pmc A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
    M L Veronese
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
    Br J Cancer 92:1846-9. 2005
    ..The combination of this standard chemotherapy regimen with gefitinib is associated with excessive toxicity, suggesting an interaction at a pharmacokinetic or pharmacodynamic level...
  14. ncbi request reprint Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
    Joshua H Bilenker
    Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 53:357-60. 2004
    ..To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors and to describe any preliminary antitumor activity associated with this regimen...
  15. ncbi request reprint Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers
    Daniel G Haller
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA
    Semin Oncol 31:10-6. 2004
    ..This review will examine recent clinical data on the use of platinum-based chemotherapies for the treatment of these gastrointestinal cancers...
  16. ncbi request reprint Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma
    Drew Moghanaki
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    JOP 12:438-44. 2011
    ..Pancreas cancer can potentially be cured by resection, but the role of adjuvant chemotherapy and/or chemoradiation has been controversial...
  17. ncbi request reprint Chemotherapy for advanced pancreatic cancer
    Daniel G Haller
    Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 56:16-23. 2003
    ..Gemcitabine has thus become the de facto standard of care for advanced pancreatic cancer, and current efforts are directed toward finding strategies that can capitalize on and extend these clinical benefits...
  18. ncbi request reprint A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer
    Weijing Sun
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer 110:2768-74. 2007
    ..The current study was conducted to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination...
  19. ncbi request reprint Future directions with angiogenesis inhibitors in colorectal cancer
    Joshua H Bilenker
    University of Pennsylvania Cancer Center, 3400 Spruce St, Philadelphia, PA 19104, USA
    Clin Colorectal Cancer 4:S86-93. 2004
    ..A better understanding of the determinants of response to antiangiogenic agents and their mechanisms of action, especially in combination with cytotoxic drugs, is crucial to future drug development...
  20. doi request reprint Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease
    Nevena Damjanov
    University of Pennsylvania, Abramson Cancer Center at Penn Presbyterian Medical Center, 51 North 39th Street, Philadelphia, PA 19104, USA
    Oncologist 14:963-9. 2009
    ....
  21. ncbi request reprint Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer
    M L Veronese
    Abramson Cancer Center, University of Pennsylvania, 51 N 39th St, MAB 103, Philadelphia, PA 19104, USA
    Eur J Cancer 40:508-14. 2004
    ..Doses recommended for further study on this schedule are irinotecan 310 mg/m(2) and UFT 300 mg/m(2)/day, with LV 60 mg/day...
  22. ncbi request reprint Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days
    Weijing Sun
    Abrahmson Family Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:5221-7. 2003
    ..2 +/- 4.5 h, respectively. BMS-184476 60 at mg/m(2) with cisplatin at 75 mg/m(2) with appropriate supportive therapy is the dose recommended for further evaluation...
  23. ncbi request reprint Adjuvant therapy for colon cancer
    Weijing Sun
    Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Curr Oncol Rep 7:181-5. 2005
    ..The application of pharmacogenetics and pharmacogenomics in adjuvant therapy for colorectal cancer will help to distinguish those patients with risk factors and to guide individualized therapy...
  24. ncbi request reprint Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
    Weijing Sun
    University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 23:4897-904. 2005
    ..Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain...
  25. ncbi request reprint Improved patient and regimen selection in locally advanced rectal cancer: who, how, and what next?
    Jared Weiss
    Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, 19104, USA
    Clin Colorectal Cancer 8:194-9. 2009
    ..Given the success of NCRT in improving local control, distant metastasis now predominates as the cause of treatment failure, and larger gains will likely be made from improvements in adjuvant chemotherapy...
  26. ncbi request reprint Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
    PETER J O'DWYER
    Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA
    J Clin Oncol 25:2313-21. 2007
    ..The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy...
  27. ncbi request reprint A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
    Neil E Martin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:5447-54. 2004
    ....
  28. ncbi request reprint Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection
    Natalie E Joseph
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 10:213-8. 2003
    ..Correct determination of nodal status is pivotal to accurate staging and predicting survival...
  29. ncbi request reprint Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer
    C M Dolinsky
    Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Surg Oncol 96:207-12. 2007
    ..Preoperative chemoradiotherapy for locally advanced rectal cancer is now considered "standard of care." However, the optimal time interval for resection after neoadjuvant therapy is unknown...
  30. ncbi request reprint Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer
    J P Stevenson
    Developmental Therapeutics Program, University of Pennsylvania, Philadelphia, USA
    J Clin Oncol 19:4081-7. 2001
    ..Functional polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene result in intracellular redistribution of folate derivatives, which may affect raltitrexed-associated cytotoxicity...
  31. ncbi request reprint Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
    P J O'Dwyer
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    J Clin Oncol 19:2413-21. 2001
    ..To investigate mechanism-directed regimens in maximizing the efficacy of fluorouracil (5-FU) in advanced colorected cancer...
  32. ncbi request reprint Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer
    D G Haller
    University of Pennsylvania Cancer Center, Philadelphia 19104-4204, USA
    Semin Oncol 28:25-30. 2001
    ..Completed and ongoing trials may support its use as monotherapy in stage II colon cancer or in combination with chemotherapy in stage III colon cancer and stage II/III rectal cancer...
  33. ncbi request reprint Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin
    D I Rosenthal
    Department of Radiation Oncology, University of Pennsylvania Cancer Center, Philadelphia, USA
    Oncology (Williston Park) 14:59-62. 2000
    ..A combination of postoperative adjuvant UFT plus leucovorin concurrent with radiation therapy should be feasible, and the design of an ongoing phase I trial is presented...
  34. ncbi request reprint Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas
    J H Lee
    Departments of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 47:945-53. 2000
    ..To determine the clinical outcomes and potential impact of adjuvant chemoradiation in patients undergoing surgical resection of ampullary carcinoma...
  35. ncbi request reprint COX-2 inhibitors in oncology
    Daniel G Haller
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Semin Oncol 30:2-8. 2003
  36. ncbi request reprint Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer
    Keith T Flaherty
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer 97:1985-90. 2003
    ..The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose of the combination...
  37. ncbi request reprint Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089
    T E Le Voyer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:2912-9. 2003
    ..To determine the relationship, in patients with adenocarcinoma of the colon, between survival and the number of lymph nodes analyzed from surgical specimens...
  38. ncbi request reprint Future directions in the treatment of pancreatic cancer
    Daniel G Haller
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Semin Oncol 29:31-9. 2002
    ..Combined-modality approaches with gemcitabine and radiation are also under active investigation...
  39. ncbi request reprint Chemotherapy for colorectal cancer
    Weijing Sun
    Hematology Oncology Division, Univeristy of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
    Hematol Oncol Clin North Am 16:969-94. 2002
    ..Future clinical trials should be focused on optimizing and individualizing therapy for patients based on their molecular profiles to achieve maximal clinical benefit...
  40. ncbi request reprint Recent advances in the treatment of gastric cancer
    W Sun
    University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Drugs 61:1545-51. 2001
    ..Although many chemotherapy regimens have been developed recently, only modest clinical efficacy has been demonstrated for advanced metastatic disease. So far, there is no single regimen considered to be standard...
  41. ncbi request reprint Metastatic PEComa arising from renal angiomyolipoma: MRI findings
    Amr K El Jack
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Magn Reson Imaging 26:159-61. 2007
    ..Both benign and malignant PEComas have been reported in diverse anatomic locations. We report the MRI features of a metastatic PEComa to the liver that originated within a renal angiomyolipoma (AML)...
  42. ncbi request reprint Long term survival after pancreatic resection for pancreatic adenocarcinoma
    N A Ahmad
    Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 96:2609-15. 2001
    ....
  43. ncbi request reprint Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
    Hans Joachim Schmoll
    Martin Luther University, Halle, Germany
    J Clin Oncol 25:102-9. 2007
    ..To report the results of a planned safety analysis from a phase III trial comparing capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil/leucovorin (FU/LV) as adjuvant therapy for stage III colon cancer...
  44. ncbi request reprint Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer
    A David McCollum
    A D McCollum, R J Mayer, C S Fuchs, Dana Farber Cancer Institute, Boston, MA, USA
    J Natl Cancer Inst 94:1160-7. 2002
    ..In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer...
  45. ncbi request reprint Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
    Heinz Joseph Lenz
    Department of Medical Oncology, University of Southern California, Los Angeles, California, USA
    Cancer 109:33-40. 2007
    ....
  46. ncbi request reprint Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    Jordan D Berlin
    Vanderbilt University, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 20:3270-5. 2002
    ....
  47. doi request reprint Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 26:2336-41. 2008
    ....
  48. ncbi request reprint Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer
    David P Kelsen
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3719-25. 2007
    ..The relationship between resection type and between tumor response and outcome were also analyzed...
  49. ncbi request reprint End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group
    Daniel J Sargent
    Department of Health Sciences Research, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:4569-74. 2007
    ..We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency...
  50. ncbi request reprint Docetaxel in advanced gastric cancer
    Daniel G Haller
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    Anticancer Drugs 13:451-60. 2002
    ..Several phase III trials are now ongoing, including a large-scale trial of docetaxel-cisplatin-5-FU versus cisplatin-5-FU. Results will show whether docetaxel improves overall response and survival, as suggested in the phase II setting...
  51. ncbi request reprint A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer
    Stephen M Hahn
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Clin Cancer Res 8:1065-72. 2002
    ..The objective of this Phase I trial was to determine the maximally tolerated dose of the FTI L-778,123 in combination with radiotherapy in non-small cell lung cancer (NSCLC) and head and neck cancer (HNC)...
  52. ncbi request reprint Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 72:108-13. 2008
    ..We performed a Phase I trial to test the safety and preliminary efficacy of adding oxaliplatin to standard preoperative chemoradiation therapy for rectal cancer...
  53. ncbi request reprint Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:4793-9. 2007
    ..We assessed the safety and efficacy of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy...
  54. ncbi request reprint Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al
    Reid B Adams
    Ann Surg Oncol 13:1281-3. 2006
  55. ncbi request reprint Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144
    Stephen R Smalley
    Kansas City Community Clinical Oncology Program CCOP, Kansas City, KS, USA
    J Clin Oncol 24:3542-7. 2006
    ..Adjuvant chemoradiotherapy after or before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. We studied three postoperative fluorouracil (FU) radiochemotherapy regimens...
  56. ncbi request reprint Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer
    Howard S Hochster
    Department of Medicine Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:676-85. 2006
    ..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented...
  57. ncbi request reprint Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group
    Mary Armanios
    Johns Hopkins University, Baltimore, MD 21205, USA
    J Clin Oncol 22:4495-9. 2004
    ..To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia...
  58. ncbi request reprint Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:484-95. 2003
    ..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized...
  59. ncbi request reprint Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:2904-11. 2003
    ....
  60. ncbi request reprint American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Al B Benson
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 22:3408-19. 2004
    ....
  61. ncbi request reprint Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285)
    Kishan J Pandya
    University of Rochester Cancer Center, Rochester, NY 14642, USA
    Oncology 66:118-25. 2004
    ..To compare the efficacy and the toxicity of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer. Patients and..
  62. ncbi request reprint Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Sharlene Gill
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1797-806. 2004
    ....
  63. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  64. ncbi request reprint New perspectives in the management of pancreas cancer
    Daniel G Haller
    Department of Medicine, The Abramson Cancer Center at the University of Pennsylvania, Philadelphia 19104 4283, USA
    Semin Oncol 30:3-10. 2003
    ..This applies not only to individual patients but also to large-scale clinical trials...
  65. ncbi request reprint Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 21:2059-69. 2003
    ..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)...
  66. ncbi request reprint Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  67. ncbi request reprint Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  68. ncbi request reprint Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Int J Radiat Oncol Biol Phys 54:386-96. 2002
    ..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
  69. ncbi request reprint Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  70. ncbi request reprint Impact of diabetes mellitus on outcomes in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:433-40. 2003
    ..To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer...
  71. ncbi request reprint A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
    Int J Radiat Oncol Biol Phys 62:1345-50. 2005
    ..This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population. Patients and..
  72. ncbi request reprint Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089
    Robert J Green
    The Helen and Harry Gray Cancer Institute, 1309 North Flagler Drive, West Palm Beach, FL 33401, USA
    Ann Intern Med 136:261-9. 2002
    ..It is unclear whether guidelines for colonoscopy screening in patients with polyps are appropriate for patients with previous colon cancer...
  73. ncbi request reprint Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus
    Mohan Suntharalingam
    Department of Radiation Oncology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21230 e mail
    J Clin Oncol 23:2325-31. 2005
    ..A Patterns of Care Study of patients treated from 1996 to 1999 evaluated the national practice for patients receiving radiation therapy for carcinoma of the esophagus in the United States...
  74. ncbi request reprint Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer
    Elizabeth A Poplin
    Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
    J Clin Oncol 23:1819-25. 2005
    ....
  75. ncbi request reprint The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study
    Mohan Suntharalingam
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Int J Radiat Oncol Biol Phys 56:981-7. 2003
    ..This study examined the evaluation and treatment schemes used during this time and compared these results to the PCS data obtained between 1992 and 1994 to identify any fundamental changes in national practice...
  76. ncbi request reprint JCO and the Public Trust
    Daniel G Haller
    J Clin Oncol 24:323-4. 2006
  77. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA 90404, USA
    Clin Cancer Res 13:6853s-6s. 2007
    ....